Delenex Therapeutics Extends Scientific Advisory Board
News Jul 07, 2015
Delenex Therapeutics AG has announced the extension of its scientific advisory board. Two world-renowned oncology specialists will bring strong clinical, scientific and drug formulation expertise to assist Delenex in developing and implementing its corporate and R&D strategy.
The new members of the advisory board are:
Roger Stupp, M.D., Professor and Chairman of the Department of Oncology at the University of Zurich, Switzerland. He also serves as the President of the European Organization for Research and Treatment of Cancer (EORTC). Prof. Stupp is known for his practice-changing novel strategies in the field of neuro-oncology, and has made significant contributions to clinical research and the launch of novel chemotherapeutics, and
Michael Weller, M.D., Professor and Chairman of the Department of Neurology, University of Zurich, Switzerland. He serves as President of the European Association of Neuro-Oncology (EANO) and as Chairman of the Brain Tumor Group of the EORTC. Prof. Weller is an internationally renowned researcher in brain tumors and has extensive experience in the diagnosis and therapy of glioblastoma and other primary brain tumors. He is involved in many clinical protocols and is instrumental in the development of novel therapies for this highly aggressive cancer.
“We are delighted and honored to have these internationally acknowledged leaders in oncology join our advisory board,” said Thomas Hecht, Delenex’ Executive Chairman. “Their expertise will be key in advancing our therapeutic programs.”
Scientists have made use of a deactivated Cas13 to guide NA Editing for Specific C to U Exchange (RESCUE) to targeted cytosine bases on RNA transcripts, and used a novel, evolved, programmable enzyme to convert unwanted cytosine into uridine -- thereby directing a change in the RNA instructions.READ MORE